Agenus Community

NasdaqCM:AGEN Community

1 Narratives written by author
0 Comments on narratives written by author
12 Fair Values set on narratives written by author

AN

AnalystConsensusTarget

Consensus Narrative from 3 Analysts

BOT/BAL Trials And Cost Reductions Will Shape Future Advances

Key Takeaways Strategic cost reduction and asset monetization aim to strengthen financials and fund key projects like BOT/BAL, enhancing potential revenues and earnings. Promising BOT/BAL clinical data and external validation boost credibility, likely supporting regulatory approvals and future market confidence.

US$7.00

FV

75.7% undervalued

0.69%

Revenue growth p.a.

0

0

1

5 days ago